Login to Your Account



Alethia, Canadian Agency In Deal For Cancer Targeting

By Donna Young


Thursday, October 4, 2007
Alethia Biotherapeutics Inc. has entered into a licensing agreement with Canada's National Research Council Biotechnology Research Institute (NRC-BRI) for the worldwide therapeutic and diagnostic rights to Clusterin-specific antibodies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription